Cartalax (20 mg Vial) Dosage Protocol

Quickstart Highlights

Cartalax is a synthetic tripeptide bioregulator (Ala‑Glu‑Asp; sequence “AED”) developed by Prof. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology^[1]. Preclinical studies indicate it may modulate fibroblast proliferation markers (Ki‑67), reduce pro‑apoptotic signaling (p53, caspase‑3), and support extracellular matrix homeostasis^[2]^[3]. Note: Published human posology for subcutaneous Cartalax is limited; this framework extrapolates from available preclinical and observational data for educational purposes only.

Reconstitute: Add 3.0 mL bacteriostatic water → ~6.67 mg/mL concentration.

Example daily range: 2,000–5,000 mcg once daily (gradual titration).

Easy measuring: At 6.67 mg/mL, 1 unit = 0.01 mL ≈ 66.7 mcg on a U‑100 insulin syringe.

Storage: Lyophilized: store at 2–8 °C (35.6–46.4 °F) or freeze at −20 °C (−4 °F) for long‑term; after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

Dosing & Reconstitution Guide

Educational framework for reconstitution and daily dosing

Standard / Gradual Approach (3 mL = ~6.67 mg/mL)

Route & Frequency: Subcutaneous, once daily. Evidence note: Specific human RCT posology for SC Cartalax is limited; this schedule references preclinical fibroblast/chondrocyte studies and general SC technique guidance^[2]^[8].

Week/Phase	Daily Dose (mcg / mg)	Units (per injection) (mL)
Weeks 1–2	2,000 mcg (2.0 mg)	30 units (0.30 mL)
Weeks 3–4	3,000 mcg (3.0 mg)	45 units (0.45 mL)
Weeks 5–8	4,000 mcg (4.0 mg)	60 units (0.60 mL)
Weeks 9–12	5,000 mcg (5.0 mg)	75 units (0.75 mL)

This schedule uses the largest practical dilution (3.0 mL) to keep per‑injection volumes within typical SC tolerability parameters (≤~1.0 mL per site)^[9]^[10].

Reconstitution Steps

Draw 3.0 mL bacteriostatic water with a sterile syringe.

Insert needle through the stopper; let the diluent run slowly down the vial wall to avoid foaming.

Gently swirl or roll until fully dissolved (do not shake).

Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Supplies Needed

Plan based on an 8–16 week daily protocol with gradual titration (average ~3.5 mg/day).

Peptide Vials (Cartalax, 20 mg each):

8 weeks ≈ 10 vials
12 weeks ≈ 15 vials
16 weeks ≈ 20 vials

Insulin Syringes (U‑100):

Per week: 7 syringes (1/day)
8 weeks: 56 syringes
12 weeks: 84 syringes
16 weeks: 112 syringes

Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.

8 weeks (10 vials): 30 mL → 3 × 10 mL bottles
12 weeks (15 vials): 45 mL → 5 × 10 mL bottles
16 weeks (20 vials): 60 mL → 6 × 10 mL bottles

Alcohol Swabs: One for the vial stopper + one for the injection site each day.

Per week: 14 swabs (2/day)
8 weeks: 112 swabs → recommend 2 × 100‑count boxes
12 weeks: 168 swabs → recommend 2 × 100‑count boxes
16 weeks: 224 swabs → recommend 3 × 100‑count boxes

View Supplier

Protocol Overview

Concise summary of the once‑daily regimen.

Goal: Support connective‑tissue homeostasis and fibroblast function based on preclinical bioregulator research^[2]^[3].

Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).

Dose Range: 2,000–5,000 mcg daily with gradual titration.

Reconstitution: 3.0 mL per 20 mg vial (~6.67 mg/mL) for accurate unit measurements.

Storage: Lyophilized: refrigerate or freeze; reconstituted: refrigerate; avoid repeated freeze–thaw.

Research Disclaimer